Daniela Curtius

Suggest Changes
Learn More
BACKGROUND Natalizumab has been recommended for the treatment of relapsing-remitting multiple sclerosis (RRMS) in patients with insufficient response to interferon-beta or glatiramer acetate(More)
  • 1